Clinical trial aimed at new therapeutic strategy for HAM by prosultiamine treatment with oral administratio
Not Applicable
- Conditions
- HTLV-I associated myelopathy (HAM)
- Registration Number
- JPRN-UMIN000005969
- Lead Sponsor
- The Department of Molecular Microbiology and Immunology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Not provided
Exclusion Criteria
HAM patients who do not approve the protocol
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The improvement of neurological signs including motor disability score and urinary disturbance with the decrease of HTLV-I-infected cells in the peripheral blood at 12 weeks after commencement.
- Secondary Outcome Measures
Name Time Method